Antimalarial drug resistance: a threat to malaria elimination

Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinin...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Menard, D, Dondorp, A
Materialtyp: Journal article
Språk:English
Publicerad: Cold Spring Harbor Laboratory 2017
_version_ 1826308349047603200
author Menard, D
Dondorp, A
author_facet Menard, D
Dondorp, A
author_sort Menard, D
collection OXFORD
description Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.
first_indexed 2024-03-07T07:18:12Z
format Journal article
id oxford-uuid:4b1d721d-0825-49f2-ae4c-14dab109d6a5
institution University of Oxford
language English
last_indexed 2024-03-07T07:18:12Z
publishDate 2017
publisher Cold Spring Harbor Laboratory
record_format dspace
spelling oxford-uuid:4b1d721d-0825-49f2-ae4c-14dab109d6a52022-09-02T09:27:04ZAntimalarial drug resistance: a threat to malaria eliminationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4b1d721d-0825-49f2-ae4c-14dab109d6a5EnglishSymplectic ElementsCold Spring Harbor Laboratory2017Menard, DDondorp, AIncreasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.
spellingShingle Menard, D
Dondorp, A
Antimalarial drug resistance: a threat to malaria elimination
title Antimalarial drug resistance: a threat to malaria elimination
title_full Antimalarial drug resistance: a threat to malaria elimination
title_fullStr Antimalarial drug resistance: a threat to malaria elimination
title_full_unstemmed Antimalarial drug resistance: a threat to malaria elimination
title_short Antimalarial drug resistance: a threat to malaria elimination
title_sort antimalarial drug resistance a threat to malaria elimination
work_keys_str_mv AT menardd antimalarialdrugresistanceathreattomalariaelimination
AT dondorpa antimalarialdrugresistanceathreattomalariaelimination